Effect of Food on Pharmacokinetics of an Inhaled Drug: A Case Study with a VLA-4 Antagonist, HMR1031

Journal of Clinical Pharmacology

Volumn 43, Issue 12, 2003, Pages 1341-1349

  Shah, Bharti ^a   Jensen, Bradford K ^a   Zhang, Jie ^a   Hunt, Thomas ^b   Rohatagi, Shashank ^a  

^a SANOFI   (France)

^b Pharmaceutical Product Development   (United States)

Author keywords

Food effect; HMR1031; Inhalation; VLA 4

Indexed keywords

3 [[2 [4,4 DIMETHYL 3 [4 [[[(2 METHYLPHENYL)AMINO]CARBONYL]AMINO]BENZYL] 2,5 DIOXOIMIDAZOLIDIN 1 YL]] 4 METHYLPENTANOYL]AMINO 3 PHENYLPROPANOIC ACID; BETA1 INTEGRIN; HMR 1031; MDL 819767; PROPIONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; ASTHMA; BILIARY EXCRETION; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; CROSSOVER PROCEDURE; DEVICE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SPECIFICITY; DRY POWDER; GASTROINTESTINAL TRACT; HALF LIFE TIME; HUMAN; HUMAN EXPERIMENT; LIVER BLOOD FLOW; MALE; NORMAL HUMAN; PROBABILITY; RANDOMIZED CONTROLLED TRIAL;

ABSORPTION; ADMINISTRATION, INHALATION; ADULT; ANTI-ASTHMATIC AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; FASTING; FOOD; HALF-LIFE; HUMANS; IMIDAZOLES; INTEGRIN ALPHA4BETA1; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; POWDERS; PROPIONIC ACIDS;

EID: 0242552664     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003258172     Document Type: Article

References (12)

1. Djukanovic R, Roche WR, Wilson JW, Beasley CR, Twentyman OP, Howarth RH, et al: Mucosal inflammation in asthma. Am Rev Respir Dis 1990;142:434-457.
2. Foster CA: VCAM-1alpha 4 integrin adhesion pathway: therapeutic target for allergic inflammatory disorders. J Allergy Clin Immunol 1996;98(6, Pt. 2):S270-S277.
3. Rohatagi S, Chapel S, Kirkesseli S, Newman S, Zhang J, Paccaly D, et al: Pharmacoscintigraphic comparison of HMR1031, a VLA-4 antagonist, in healthy volunteers following delivery via a nebulizer and a dry powder inhaler (DPI). Am J Ther; accepted for publication.
4. Food and Drug Administration: Guidance for Industry: Food-Effect Bioavailability and Bioequivalence Studies. Rockville, MD: FDA (CDER), 2001.
5. Derendorf H, Hochhaus G, Rohatagi S, Mollmann H, Barth J, Sourgens H, et al: Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. J Clin Pharmacol 1995;35:302-305.
6. Donnelly R, Seale P: Clinical pharmacokinetics of inhaled budesonide. Clin Pharmacokinet 2001;40(6):427-440.
7. Rowland M, Tozer TN: Clinical Pharmacokinetics: Concepts and Application. 3rd ed. Baltimore: Williams & Wilkins, 1995.
8. Davies B, Morris T: Physiological parameters in laboratory animals and humans. Pharm Res 1993;10:1093-1095.
9. Burggraaf J, Schoemaker HC, Cohen AF: Assessment of changes in liver blood flow after food intake-comparison of ICG clearance and echo-Doppler. Br J Clin Pharmacol 1996;42(4):499-502.
10. Schoemaker RC, Burggraaf J, Cohen AF: Assessment of hepatic blood flow using continuous infusion of high clearance drugs. Br J Clin Pharmacol 1998;45(5):463-469.
11. Kemme MJ, Burggraaf J, Schoemaker RC, Paulson S, Karim A, Lentjes EG, et al: The influence of reduced liver blood flow on the pharmacokinetics and pharmacodynamics of recombinant tissue factor pathway inhibitor. Clin Pharmacol Ther 2000;67(5):504-511.
12. Heinig R: Clinical pharmacokinetics of nisoldipine coat-core. Clin Pharmacokinet 1998;35(3):191-208.